PT2992020T - Células efetoras imunes projetadas específicas do recetor de antígeno quimérico cs1 - Google Patents
Células efetoras imunes projetadas específicas do recetor de antígeno quimérico cs1Info
- Publication number
- PT2992020T PT2992020T PT147914949T PT14791494T PT2992020T PT 2992020 T PT2992020 T PT 2992020T PT 147914949 T PT147914949 T PT 147914949T PT 14791494 T PT14791494 T PT 14791494T PT 2992020 T PT2992020 T PT 2992020T
- Authority
- PT
- Portugal
- Prior art keywords
- effector cells
- antigen receptor
- chimeric antigen
- immune effector
- engineered immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361819141P | 2013-05-03 | 2013-05-03 | |
US201361876492P | 2013-09-11 | 2013-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2992020T true PT2992020T (pt) | 2020-02-28 |
Family
ID=51844005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147914949T PT2992020T (pt) | 2013-05-03 | 2014-05-02 | Células efetoras imunes projetadas específicas do recetor de antígeno quimérico cs1 |
Country Status (17)
Country | Link |
---|---|
US (3) | US10358494B2 (pt) |
EP (2) | EP3663320A1 (pt) |
JP (3) | JP6856188B2 (pt) |
KR (1) | KR102098985B1 (pt) |
CN (2) | CN105377897A (pt) |
AU (2) | AU2014259675B2 (pt) |
BR (1) | BR112015027567B1 (pt) |
CA (1) | CA2910666A1 (pt) |
DK (1) | DK2992020T3 (pt) |
ES (1) | ES2777940T3 (pt) |
HK (1) | HK1218925A1 (pt) |
HU (1) | HUE048312T2 (pt) |
IL (1) | IL242315B (pt) |
MX (1) | MX370173B (pt) |
PL (1) | PL2992020T3 (pt) |
PT (1) | PT2992020T (pt) |
WO (1) | WO2014179759A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2992020T3 (pl) * | 2013-05-03 | 2020-06-01 | Ohio State Innovation Foundation | Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 |
WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
AU2015357485B2 (en) * | 2014-12-05 | 2020-10-15 | City Of Hope | CS1 targeted chimeric antigen receptor-modified T cells |
EP3240551A4 (en) * | 2014-12-31 | 2018-08-08 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
ES2789330T3 (es) * | 2015-01-29 | 2020-10-26 | Univ Minnesota | Receptores de antígeno quimérico, composiciones y métodos |
AU2016219785B2 (en) | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
US11045543B2 (en) | 2015-04-06 | 2021-06-29 | Cytoimmune Therapeutics, Inc. | EGFR-directed car therapy for glioblastoma |
EP3298046A1 (en) * | 2015-05-20 | 2018-03-28 | Cellectis | Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy |
IL309167A (en) * | 2015-06-10 | 2024-02-01 | Immunitybio Inc | Modified NK-92 cells for cancer treatment |
US11478555B2 (en) | 2015-08-17 | 2022-10-25 | Seoul National University R&Db Foundation | Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof |
EP3360961B1 (en) * | 2015-10-08 | 2023-11-22 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
KR20180101540A (ko) * | 2016-01-15 | 2018-09-12 | 이투빅스 코포레이션 | T 세포 면역요법을 위한 방법 및 조성물 |
WO2017130223A2 (en) | 2016-01-29 | 2017-08-03 | Virocan Therapeutics Pvt. Ltd. | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
EP3433269B1 (en) | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
EP3445407B1 (en) | 2016-04-22 | 2022-12-14 | CRAGE medical Co., Limited | Compositions and methods of cellular immunotherapy |
WO2018022646A1 (en) | 2016-07-25 | 2018-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
CN106279432B (zh) * | 2016-08-10 | 2019-09-20 | 深圳市再生之城生物医药技术有限公司 | 一种vc-car分子及在清除hiv-1感染细胞中的应用 |
CN108699163B (zh) * | 2016-09-28 | 2021-11-19 | 阿思科力(苏州)生物科技有限公司 | 一种多基因重组嵌合抗原受体分子及其应用 |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE |
JP7033601B2 (ja) * | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
JP2020511498A (ja) * | 2017-03-20 | 2020-04-16 | シティ・オブ・ホープCity of Hope | Alアミロイドーシスの治療のためのcs1標的化キメラ抗原レセプター改変t細胞 |
CA3059643A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
US20200129554A1 (en) * | 2017-07-07 | 2020-04-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with mutated cd28 costimulatory domains |
US11639508B2 (en) | 2017-07-14 | 2023-05-02 | The Johns Hopkins University | Engineered TSC2 |
TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
WO2019069125A1 (en) * | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
WO2019178463A1 (en) * | 2018-03-16 | 2019-09-19 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors with mutated cd28 phosphorylation sites |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
US11951131B2 (en) | 2018-07-03 | 2024-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SLAMF7 chimeric antigen receptors |
WO2020010341A1 (en) * | 2018-07-05 | 2020-01-09 | Emory University | Transduction of innate immunocompetent cells using aav6 |
WO2020025039A1 (zh) * | 2018-08-03 | 2020-02-06 | 南京驯鹿医疗技术有限公司 | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 |
EP3894011A1 (en) | 2018-12-11 | 2021-10-20 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
KR20210148293A (ko) | 2019-04-03 | 2021-12-07 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
MX2021015097A (es) | 2019-06-12 | 2022-04-01 | Obsidian Therapeutics Inc | Composiciones de ca2 y metodos para regulación ajustable. |
EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
CN114729383A (zh) | 2019-07-02 | 2022-07-08 | 弗莱德哈钦森癌症研究中心 | 重组ad35载体及相关基因疗法改进 |
CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
AR120430A1 (es) * | 2019-11-08 | 2022-02-16 | Humanigen Inc | Células car-t dirigidas a epha3 para el tratamiento de tumores |
WO2022002919A1 (en) * | 2020-06-29 | 2022-01-06 | Julius-Maximilians-Universität Würzburg | Slamf7 cars |
US20230295331A1 (en) * | 2020-08-06 | 2023-09-21 | Promab Biotechnologies, Inc. | Cs1- antibody and anti-cs1-car-t cells |
WO2022063302A1 (zh) * | 2020-09-25 | 2022-03-31 | 克莱格医学有限公司 | 免疫细胞活性调节 |
CA3202218A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
CA2406993A1 (en) * | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
JP2012507555A (ja) | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗cs1抗体の使用 |
TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
EP3115373B1 (en) * | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
EA035033B1 (ru) * | 2010-11-22 | 2020-04-20 | Иннейт Фарма Са | Способ лечения гематологического предракового или гематологического ракового заболеваний |
DK3214091T3 (en) * | 2010-12-09 | 2019-01-07 | Univ Pennsylvania | USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER |
EP2765193B1 (en) * | 2011-10-07 | 2017-08-09 | Mie University | Chimeric antigen receptor |
BR112014011912A2 (pt) | 2011-11-16 | 2017-05-16 | Amgen Inc | método para o tratamento de um mamífero que tem um tumor |
ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
US9518277B2 (en) | 2012-12-07 | 2016-12-13 | Terravia Holdings, Inc. | Genetically engineered microbial strains including Chlorella protothecoides lipid pathway genes |
CN103224561A (zh) | 2013-01-16 | 2013-07-31 | 天津大学 | 葡萄球菌肠毒素小分子抗体及制备方法及用途 |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
PL2992020T3 (pl) * | 2013-05-03 | 2020-06-01 | Ohio State Innovation Foundation | Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 |
CA2927543C (en) | 2013-10-15 | 2021-07-20 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
EP3765042A4 (en) * | 2018-03-16 | 2021-12-29 | Cytoimmune Therapeutics, Inc. | Bispecific antibody car cell immunotherapy |
-
2014
- 2014-05-02 PL PL14791494T patent/PL2992020T3/pl unknown
- 2014-05-02 PT PT147914949T patent/PT2992020T/pt unknown
- 2014-05-02 US US14/888,877 patent/US10358494B2/en active Active
- 2014-05-02 WO PCT/US2014/036684 patent/WO2014179759A1/en active Application Filing
- 2014-05-02 KR KR1020157033493A patent/KR102098985B1/ko active IP Right Grant
- 2014-05-02 CA CA2910666A patent/CA2910666A1/en active Pending
- 2014-05-02 AU AU2014259675A patent/AU2014259675B2/en active Active
- 2014-05-02 CN CN201480030178.9A patent/CN105377897A/zh active Pending
- 2014-05-02 JP JP2016512083A patent/JP6856188B2/ja active Active
- 2014-05-02 BR BR112015027567-2A patent/BR112015027567B1/pt active IP Right Grant
- 2014-05-02 CN CN202210255676.XA patent/CN115028735A/zh active Pending
- 2014-05-02 DK DK14791494.9T patent/DK2992020T3/da active
- 2014-05-02 HU HUE14791494A patent/HUE048312T2/hu unknown
- 2014-05-02 EP EP20150396.8A patent/EP3663320A1/en active Pending
- 2014-05-02 EP EP14791494.9A patent/EP2992020B1/en active Active
- 2014-05-02 MX MX2015015182A patent/MX370173B/es active IP Right Grant
- 2014-05-02 ES ES14791494T patent/ES2777940T3/es active Active
-
2015
- 2015-10-28 IL IL242315A patent/IL242315B/en active IP Right Grant
-
2016
- 2016-06-17 HK HK16106998.1A patent/HK1218925A1/zh unknown
-
2017
- 2017-05-17 US US15/597,436 patent/US10227409B2/en active Active
-
2019
- 2019-04-18 JP JP2019079616A patent/JP2019146579A/ja active Pending
- 2019-05-31 AU AU2019203823A patent/AU2019203823B2/en active Active
- 2019-07-09 US US16/506,327 patent/US11845794B2/en active Active
-
2021
- 2021-07-16 JP JP2021118254A patent/JP7221338B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218925A1 (zh) | -特異性嵌合抗原受體工程化的免疫效應細胞 | |
IL290459A (en) | Modified t cells - targeted chimeric antigen receptor cs1 | |
HK1222186A1 (zh) | 嵌合抗原受體 | |
HK1215267A1 (zh) | 嵌合抗原受體 | |
HK1213922A1 (zh) | 嵌合抗原受體 | |
HK1222678A1 (zh) | 特異性嵌合抗原受體及其用途 | |
EP3087101A4 (en) | Regulatable chimeric antigen receptor | |
EP3057991B8 (en) | Chimeric antigen receptor t cell switches and uses thereof | |
HK1212728A1 (zh) | 多鏈嵌合抗原受體和其用途 | |
HK1222674A1 (zh) | 工程化嵌合抗原受體 細胞的人應用 | |
EP3057994A4 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
EP2866833A4 (en) | CRYSTALLINE ANTIBODIES AGAINST HUMAN IL-23 | |
EP2765193A4 (en) | CHIMERIC ANTIGEN RECEPTOR | |
EP2830660A4 (en) | ANTI-SEMA4D ANTIBODIES AND EPITOPES | |
PT2821416T (pt) | Anticorpo de recetor il-23 anti- humano inovador | |
ZA201508068B (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
GB201310565D0 (en) | Antigen immunogenicity characterisation assay |